Procsal D A, Okamura W H, Norman A W
J Biol Chem. 1975 Nov 10;250(21):8382-8.
The mechanism by which 1 alpha,25-dihydroxycholecalciferol (1alpha,25-(OH)2D3), the biologically active metabolite of cholecalciferol (vitamin D3), stimulates intestinal calcium absorption has been shown to involve an interaction of the steroid with a specific cytosol-chromatin receptor system in this target organ. Thus, 1alpha,12(OH)2D3 binds to a specific cytoplasmic receptor protein and then, following a temperature-dependent step, becomes associated with a finite number of chromatin acceptor sites prior to the initiation of the physiological response. In this respect, 1alpha,25(OH) 2D3 is similar to a number of other steroid hormones. In this investigation, studies were performed to help define the essential structural features required for interaction of 1alpha,25-(OH)2D3 with its intestinal receptor system, and presumably, for biological activity. To this end, competition studies utilizing a series of closely related structural analogs of cholecalciferol were carried out by means of a competitive binding assay highly specific for 1alpha,25(OH)2D3. The competitive binding assay employed in this study is dependent upon the ability to duplicate, in vitro, the conditions which permit the saturable binding of 1alpha,25-(OH)2[3H]D3 to chick intestinal chromatin, in vivo. Optimal conditions for this assay were achieved by the incubation of a reconstituted intestinal receptor system consisting of separately isolated cytosol and Triton X-100 chromatin fractions at 25 degrees for 45 min with 2.0 X 10-8 M 1alpha,25-(OH)2[3H]D3. Maximal binding of about 21 to 24 pmol of radioactive steroid bound per chick intestinal chromatin occurred under these conditions. The ability of the various analogs to compete with the radioactive hormone was assessed by virtue of a decrease in the amount of radioactive steroid bound to the chromatin in the presence of increasing concentrations of nonradioactive analog.
胆钙化醇(维生素D3)的生物活性代谢产物1α,25 - 二羟基胆钙化醇(1α,25-(OH)2D3)刺激肠道钙吸收的机制已表明涉及该类固醇与该靶器官中特定胞质溶胶 - 染色质受体系统的相互作用。因此,1α,25(OH)2D3与一种特定的细胞质受体蛋白结合,然后,经过一个温度依赖性步骤,在生理反应开始之前与有限数量的染色质受体位点结合。在这方面,1α,25(OH)2D3与许多其他类固醇激素相似。在本研究中,进行了多项研究以帮助确定1α,25-(OH)2D3与其肠道受体系统相互作用以及可能的生物活性所需的基本结构特征。为此,通过对1α,25(OH)2D3具有高度特异性的竞争性结合测定法,利用一系列与胆钙化醇结构密切相关的类似物进行竞争研究。本研究中使用的竞争性结合测定法依赖于在体外复制允许1α,25-(OH)2[3H]D3在体内与鸡肠道染色质进行饱和结合的条件的能力。通过将由分别分离的胞质溶胶和Triton X - 100染色质组分组成的重组肠道受体系统在25℃下与2.0×10 - 8M 1α,25-(OH)2[3H]D3孵育45分钟,实现了该测定法的最佳条件。在这些条件下,每只鸡肠道染色质发生约21至24 pmol放射性类固醇的最大结合。通过在存在浓度不断增加的非放射性类似物的情况下,与染色质结合的放射性类固醇量的减少来评估各种类似物与放射性激素竞争的能力。